GlobalRPH - Pharma Industry News

Medical News

< back to feeds
Pharma Industry News
U.S. Farmers Continue To Favor Biotech Crop Varieties American farmers have adopted genetically engineered (GE) crops widely since their introduction in 1996 because of the tangible benefits that biotech varieties deliver. According to the U.S. Department of Agriculture, U.S. farmers have embraced biotech varieties of soybeans, cotton and corn at the rate of 91 percent, 88 percent and 85 percent, respectively. ...more	20 Nov 2009
BIO Announces Presidents Bill Clinton And George W. Bush To Provide Keynote At 2010 BIO International Convention The Biotechnology Industry Organization (BIO) announces that Presidents Bill Clinton and George W. Bush, the 42nd and 43rd Presidents of the United States, will appear together for a moderated discussion at the 2010 BIO International Convention, which will be held May 3-6 in Chicago, Ill. at McCormick Place. Presidents Clinton and Bush, who served in the White House for 16 years, will discuss a wide variety of issues relating to both domestic and foreign policy. ...more	20 Nov 2009
Daschle Still Making Voice Heard On Health Care The Hill reports that former Senate Majority Leader Tom Daschle helped Obama Administration officials strategize to win health care reform votes from Senators on Capitol Hill Wednesday. ...more	20 Nov 2009
Lawmakers Call For Inquiry Into Pharmaceutical Company Price Hikes Reuters: "Congressional Democrats are seeking government investigations into recent price increases of brand-name prescription drugs, as Congress finalizes an overhaul of the healthcare system. ...more	20 Nov 2009
Op-Eds: HIV Travel Ban; Improving Sanitation; Counterfeit Drugs 'Blot' On U.S. HIV/AIDS Leadership Removed A "blot" on U.S. HIV/AIDS leadership "ended last month when President [Barack] Obama lifted the prohibition" that kept HIV-positive foreigners from visiting the U.S. or seeking residency, according to a ...more	20 Nov 2009
Pfizer, DNDi Partner To Identify NTD Drugs; Sanofi-Aventis, Medicines For Malaria Launch Drug Study Pfizer and the Drugs for Neglected Diseases Initiative (DNDi) on Wednesday announced plans to team up in an effort to identify new drug candidates for the treatment of three tropical diseases, the Associated Press/Business Week reports. The scientists will test the efficacy of Pfizer drug candidates against sleeping sickness, visceral leishmaniasis, and Chagas disease. ...more	20 Nov 2009
FDA Issues 22 Warning Letters To Web Site Operators The U.S. Food and Drug Administration completed a coordinated, weeklong, international effort, called the International Internet Week of Action (IIWA), intended to curb illegal actions involving medical products. ...more	20 Nov 2009
Adamas Pharmaceuticals Expands Clinical Study For Triple-Combination Antiviral Drug Therapy In Immune Compromised Patients Adamas Pharmaceuticals, Inc., a privately held company, announced that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. ...more	20 Nov 2009
Generic And Brand-Name Drug Makers Face Off "Teva Pharmaceuticals, a leading manufacturer of generic drugs, has been aggressively lobbying Congress to scrap provisions in the health care bills it claims would shut it out of the biologic drug market for too long," Roll Call reports. Lobbyists for the biologics makers have charged, however, that Teva is hypocritical because it is fighting to restrict generic production of its own brand-name product. ...more	19 Nov 2009
Zydena Is Efficacious In Once Daily Dosing For Erectile Dysfunction/Positive BPH Results Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in Korea was a randomized, double-blind, placebo-controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. ...more	19 Nov 2009
Merz Pharmaceuticals Announces Approval Of Post-stroke Upper Limb Spasticity Indication For Xeomin(R) In The EU Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries. Xeomin® was already granted approval for post-stroke spasticity of the upper limb in early 2009 in Canada, Mexico and Argentina. ...more	19 Nov 2009
Epiphany Announces Positive Results From Its Phase 2b Trial In Shingles Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash. ...more	19 Nov 2009
CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference In San Francisco CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA. Dr. ...more	19 Nov 2009
Clinical Budgeting And Contracting Excellence Strategies That Empower Investigators And Support Patient Enrollment 7-8 Dec, 2009, Princeton New Jersey Alarming trends captured in clinical study metrics show the glaring discrepancy between the miniscule number of sites that are able to enroll the amount of patients study sponsors are requesting and the amount of sites that cannot. This enrollment inability leads to trial stoppages, lost revenue and most importantly the delay of new treatments used to combat diseases that are available for the population. ...more	19 Nov 2009
White House Deal With Drug Makers May Be Unraveling "Congressional Democrats' intensifying efforts to pay for their healthcare overhaul and provide more relief for consumers are threatening to unravel a White House deal with the pharmaceutical industry and turn one of Washington's most powerful lobbies against the legislation," the Los Angeles Times reports. ...more	18 Nov 2009
InterMune Announces Modification To On-Going Phase 2b Study Of ITMN-191 In Patients With Chronic HCV Infection InterMune, Inc. (Nasdaq: ITMN) announced that the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin) in HCV treatment-naive patients has been modified. The Phase 2b study has four dosage cohorts: SOC; 300mg q8h plus SOC; 600mg q12h plus SOC and 900mg q12h plus SOC. To date, approximately 175 patients have been enrolled in the study. ...more	18 Nov 2009
NeurogesX To Hold Conference Call To Discuss FDA Approval Of Qutenza(TM) (capsaicin) 8% Patch For Treatment Of Postherpetic Neuralgia (PHN) NeurogesX, Inc. (Nasdaq: NGSX) announces that it will hold a conference call at 8:30a.m. ET (5:30a.m. PT) to discuss the U.S. Food and Drug Administration (FDA) approval of Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia (PHN), the nerve pain which can follow shingles. ...more	18 Nov 2009
Poniard Pharmaceuticals Announces Updated Positive Clinical Data From Phase 2 Trial Of Picoplatin In Colorectal Cancer Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). ...more	18 Nov 2009
Vaccine To Treat Nicotine Addiction Steps Closer To Market As Companies Agree Option Deal An experimental vaccine called NicVAX, designed to treat nicotine addiction that works by stopping the drug from reaching the brain, moved a step closer to the market when the vaccine developer Nabi Biopharmaceuticals (Nabi), based in Rockville, Maryland, US agreed an option and licensing deal with GlaxoSmithKline Biologicals SA (GSK), based in Brussels, Belgium. ...more	18 Nov 2009
Drug Makers Hike Prices, Lobby Hard As Reform Efforts Progress Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect. ...more	17 Nov 2009
Pages of Results: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 [Next] [Last Page]
Pharma Industry News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.